Quidel Corp (QDEL) Tops Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
February 12, 2020 4:10 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and the year ended December 31, 2019.
Fourth Quarter 2019 Highlights
Total revenue increased 15% to $152.2 million, compared with $132.6 million in the fourth quarter of 2018. Cardiac Immunoassay revenue increased 5% to $65.8 million. Molecular Diagnostic Solutions revenue was $7.1 million, 21% growth from the fourth quarter of 2018. Influenza revenue increased 44% to $50.3 million, compared with $34.9 million in the fourth quarter of... More